JLE

European Journal of Dermatology

MENU

Lymphomatoid papulosis during upadaci-tinib treatment for rheumatoid arthritis Volume 32, numéro 1, January-February 2022

Illustrations


  • Figure 1.
Auteurs
1 Department of Dermatology, Japanese Red Cross Kitami Hospital, Kitami, Japan
2 Department of Dermatology, Japanese Red Cross Kitami Hospital, Kitami, Japan
3 Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan

Upadacitinib is an orally administered selective Janus kinase 1 (JAK1) inhibitor that is highly effective against multiple inflammatory diseases, including rheumatoid arthritis (RA), psoriatic arthritis and atopic dermatitis. Janus kinase (JAK) inhibitors induce several adverse effects, such as herpes zoster, serious and opportunistic infections, and thromboembolic events. JAK inhibitors are also believed to increase the risk of malignancies, including lymphoproliferative disorders, by reducing antitumor [...]